|
May 2
|
Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates
|
|
May 2
|
Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights
|
|
Apr 18
|
Owning 36% shares,institutional owners seem interested in Shattuck Labs, Inc. (NASDAQ:STTK),
|
|
Apr 9
|
Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024
|
|
Apr 1
|
Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference
|
|
Mar 5
|
Shattuck Labs Full Year 2023 Earnings: Beats Expectations
|
|
Mar 4
|
Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors
|
|
Dec 21
|
Shattuck Labs Announces $50 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
|
|
Dec 21
|
We're Keeping An Eye On Shattuck Labs' (NASDAQ:STTK) Cash Burn Rate
|
|
Dec 5
|
Shattuck Labs to Host Investor Call and Webcast to Share Initial Clinical Trial Data from Phase 1A/B Dose-Expansion Cohorts in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53m Acute Myeloid Leukemia (AML) and Review of Dose-Escalation...
|
|
Nov 6
|
Shattuck Labs to Report Third-Quarter 2023 Financial Results on November 9, 2023
|
|
Nov 2
|
Shattuck Labs to Present Topline Data from Phase 1 A/B Clinical Trial of SL-172154 in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) Patients at the American Society of Hematology (ASH) 2023 An...
|